| Identification | More | [Name]
2-[(2S)-6-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid | [CAS]
111902-57-9 | [Synonyms]
2-[(2s)-6-[[(1s)-1-ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
(+)-[(2s,6r)-6-[[(s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-5-oxo-2-(2-thienyl)perhydro-1,4-thiazepin-4-yl]acetic acid
TEMOCAPRIL
temocaprilat
TEMOCAPRIL DISCONTINUED SEE T017301
Temocapil
(2S,6R)-6-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic Aci
1,4-Thiazepine-4(5H)-acetic acid, 6-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-, (2S,6R)-(9CI)
1,4-Thiazepine-4(5H)-acetic acid, 6-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-, [2S-[2a,6b(R*)]]-
2-((2S,6R)-6-((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-ylamino)-5-oxo-2-(thiophen-2-yl)-1,4-thiazepan-4-yl)aceticacid
2-[(2S)-6-[[(1S)-1-Ethoxycarbonyl-3-phenyl-propyl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
(2S,6R)-6-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5H)-acetic Acid
[[(2S,6R)-6-[[(S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]hexahydro-5-oxo-2-(2-thienyl)-1,4-thiazepin]-4-yl]acetic acid
2-[(2S,6R)-6-[[(S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-5-oxo-2-(2-thienyl)-2,5,6,7-tetrahydro-1,4-thiazepine-4(3H)-yl]acetic acid | [Molecular Formula]
C23H28N2O5S2 | [MDL Number]
MFCD00865951 | [Molecular Weight]
476.609 | [MOL File]
111902-57-9.mol |
| Chemical Properties | Back Directory | [Appearance]
Crystalline Powder | [Melting point ]
1680C | [alpha ]
23 +40° (c = 1.1 in DMF) | [Boiling point ]
717.4±60.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [form ]
Powder | [pka]
3.73±0.10(Predicted) | [color ]
Crystalline | [Usage]
Angiotensin-converting enzyme (ACE) inhibitor. Hydrolyzed in vivo to the active diacid metabolite | [CAS DataBase Reference]
111902-57-9(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Powder | [Uses]
Angiotensin-converting enzyme (ACE) inhibitor. Hydrolyzed in vivo to the active diacid metabolite | [Uses]
Angiotensin-converting enzyme (ACE) inhibitor. Hydrolyzed in vivo to the active diacid metabolite. | [Definition]
ChEBI: Temocapril is a dipeptide. | [in vivo]
Temocapril (10 mg/kg; p.o.; 21 d) enhances cardiomyocyte thioredoxin expression and ameliorates autoimmune myocarditis[3].
Temocapril (30 mg/kg; p.o.; daily; for 4 weeks) suppresses Angiotensin I-induced hypertension, plasma and renal ACE activity, but fails to reduce the level of Ang II in the kidney[4].
| Animal Model: | Experimental autoimmune myocarditis (EAM) rat model[3] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; administration by water; 21 days | | Result: | Ameliorated EAM and prevented cellular proteins from oxidation.
Enhanced cardiomyocyte redox regulatory protein TRX expression.
|
| Animal Model: | Male Sprague Dawley rats[4] | | Dosage: | 30 mg/kg | | Administration: | Oral gavage, daily, for 4 weeks | | Result: | Suppressed the blood pressure elevation induced by Ang I.
|
|
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|